REPL · Replimune Group, Inc.
$15.04
-0.25 (-1.64%)
At close · Sep 4
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.42B
Shares
94.22M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-06 | Replimune TUDRIQEV FDA Accelerated Approval Investor Call | Webcast |
| 2026-03-09 | Leerink Partners 2026 Global Healthcare Conference | Conference |
| 2026-01-14 | 44th Annual J.P. Morgan Healthcare Conference | Conference |
Source: https://ir.replimune.com/
Key facts
CIK
1737953
CUSIP
76029N106
13F (30d)
145 filings
145 filers
Visit website
Investor relations